Table 3.
Multivariate model for risk of skeletal-related events
| Hazard ratio (95% CI) | p value | ||
|---|---|---|---|
| Zoledronic acid vs clodronic acid | 0·72 (0·62–0·84) | <0·0001 | |
| CTD vs CVAD (intensive pathway) | 0·91 (0·76–1·10) | 0·3399 | |
| CTDa vs melphalan+prednisolone (non-intensive pathway) | 0·75 (0·60–0·94) | 0·0141 | |
| Serum calcium concentration (high vs low) | 1·31 (1·11–1·55) | 0·0012 | |
| Serum creatinine concentration (high vs low) | 0·93 (0·77–1·12) | 0·4362 | |
| Haemoglobin concentration (high vs low) | 1·08 (0·92–1·26) | 0·3489 | |
| Platelets (high vs low) | 1·19 (0·93–1·53) | 0·1623 | |
| Skeletal-related events at baseline* | |||
| No vs yes | 0·35 (0·28–0·44) | <0·0001 | |
| Missing vs yes | 0·83 (0·46–1·52) | 0·5532 | |
| Centre† | .. | <0·0001 | |
CTD=cyclophosphamide, thalidomide, and dexamethasone. CVAD=cyclophosphamide, vincristine, doxorubicin, and dexamethasone. CTDa=attenuated CTD.
*
Any event, including diagnosis of a osteolytic lesion.
†
Overall p value, but not hazard ratio, reported for 120 centres.